natgillin/translations-raw huggingface dataset:
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to medical prescription
UVJETI ILI OGRANIČENJA VEZANI UZ OPSKRBU I PRIMJENU
Non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid > 3 g/day), and non-selective NSAIDs When angiotensin II receptor antagonists are administered simultaneously with NSAIDs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Kad se antagonisti receptora angiotenzina II primjenjuju istovremeno s NSAIL (npr. selektivnim COX-2 inhibitorima, acetilsalicilnom kiselinom (> 3 g na dan) i neselektivnim NSAIL), može doći do slabljenja antihipertenzivnog učinka.
INFORMATION IN BRAILLE Ipreziv 20 mg
16. PODACI NA BRAILLEOVOM PISMU Ipreziv 20 mg
- If you suffer from other coexisting illnesses such as severe kidney disease or heart failure your doctor will decide on the most appropriate starting dose.
- Ako istovremeno bolujete od drugih bolesti, poput teške bolesti bubrega ili zatajenja srca,
Ipreziv was compared with placebo and active comparators in two 6-week randomized, double blind studies.
U dva randomizirana, dvostruko slijepa ispitivanja u trajanju od 6 tjedana, Ipreziv je bio uspoređen s placebom i aktivnom kontrolom.
Caution should be exercised in hypertensive patients with severe renal impairment and end stage renal disease as there is no experience of use of Ipreziv in these patients (see sections 4.4 and 5.2).
Potreban je oprez u bolesnika s hipertenzijom i teškim oštećenjem funkcije bubrega ili završnim stadijem bubrežne bolesti, jer nema iskustva s primjenom Ipreziva u tih bolesnika (vidjeti dio 4.4 i 5.2).
- If you suffer from mild or moderate liver disease your doctor may recommend a lower starting
- Ako bolujete od blage do umjerene bolesti jetre, liječnik Vam može preporučiti nižu početnu dozu od 20 mg jedanput na dan.
What Ipreziv looks like and contents of the pack Ipreziv are white round tablets debossed “ASL” on one side and either “20”, “40” or “80” on the other.
Ipreziv su bijele okrugle tablete s utisnutom oznakom “ASL” na jednoj strani i “20”, “40” ili “80” na drugoj.
(medicines to relieve pain and inflammation) - Aspirin (acetylsalicyclic acid) if taking more than 3 g per day (medicine to relieve pain and
- litij (lijek za tegobe s mentalnim zdravljem) - nesteroidne protuupalne lijekove, kao što su ibuprofen, diklofenak ili celekoksib (lijekovi za ublažavanje bolova i upale) - aspirin (acetilsalicilna kiselina), ako uzimate više od 3 g na dan (lijek za ublažavanje bola i upale)
See also information under the heading “Do not take Ipreziv”.
Vidjeti također informacije pod naslovom “Nemojte uzimati Ipreziv” Morate obavijestiti liječnika ako mislite da ste trudni (ili biste mogli zatrudnjeti).
Rare side effects affecting less than 1 in 1000 people: - Changes in blood test results including decreased levels of a protein in the red blood cells
- promjere rezultata krvnih pretraga uključujući snižene razine jednog proteina u crvenim krvnim stanicama (hemoglobina).
Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of lithium and angiotensin-converting enzyme inhibitors.
Litij Tijekom istovremene primjene litija i inhibitora angiotenzin-konvertirajućeg inhibitora zabilježena su reverzibilna povećanja koncentracije litija.
What Ipreziv contains - The active substance is azilsartan medoxomil (as potassium) either 20 mg, 40 mg or 80 mg - The other ingredients are mannitol, fumaric acid, sodium hydroxide, hydroxypropylcellulose,
SADRŽAJ PAKIRANJA I DRUGE INFORMACIJE Što Ipreziv sadrži - Djelatna tvar je azilsartanmedoksomil (u obliku kalijeve soli) od 20 mg, 40 mg ili 80 mg
NAME OF THE MEDICINAL PRODUCT Ipreziv 20 mg tablets
NAZIV LIJEKA Ipreziv 20 mg tablete
- have severe liver disease - have heart problems (including heart failure, recent heart attack) - have ever had a stroke - have low blood pressure or feel dizzy or lightheaded - are vomiting, have recently had severe vomiting, or have diarrhoea - have elevated levels of potassium in your blood - have a disease of the adrenal gland called primary hyperaldosteronism - have been told that you have a narrowing of the valves in your heart (called “aortic or mitral valve stenosis”) or that the thickness of your heart muscle is abnormally increased (called
- ako imate povišene razine kalija u krvi - ako imate bolest nadbubrežnih žlijezda koja se zove primarni hiperaldosteronizam - ako su Vam rekli da imate suženje srčanih zalistaka (što se zove “aortalna ili mitralna stenoza”)
Common side effects affecting less than 1 in 10 people: - Dizziness - Diarrhoea - Increased blood creatine phosphokinase (an indicator of muscle damage).
- omaglica - proljev - povišena kreatin fosfokinaza u krvi (pokazatelj oštećenja mišića).
NAME OF THE MEDICINAL PRODUCT Ipreziv 80 mg tablets
NAZIV LIJEKA Ipreziv 80 mg tablete
Clinic SBP: LS Mean Change from Baseline (BL) to Week 6 (mm Hg) (LOCF) Study 1
tjedna (mm Hg) (LOCF) Ispitivanje 1
NAME OF THE MEDICINAL PRODUCT Ipreziv 40 mg tablets azilsartan medoxomil
NAZIV LIJEKA Ipreziv 40 mg tablete azilsartanmedoksomil
NAME OF THE MEDICINAL PRODUCT Ipreziv 20 mg tablets azilsartan medoxomil
NAZIV LIJEKA Ipreziv 20 mg tablete azilsartanmedoksomil
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 80 mg of azilsartan medoxomil (as potassium).
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna tableta sadrži 80 mg azilsartanmedoksomila (u obliku kalijeve soli).
NAME OF THE MEDICINAL PRODUCT Ipreziv 80 mg tablets azilsartan medoxomil
NAZIV LIJEKA Ipreziv 80 mg tablete azilsartanmedoksomil
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg of azilsartan medoxomil (as potassium).
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna tableta sadrži 20 mg azilsartanmedoksomila (u obliku kalijeve soli).
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 40 mg of azilsartan medoxomil (as potassium).
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna tableta sadrži 40 mg azilsartanmedoksomila (u obliku kalijeve soli).
However some people may feel tired or dizzy when taking Ipreziv and if this happens to you, do not drive or use any tools or machines.
Međutim, neke osobe mogu osjećati umor ili omaglicu dok uzimaju Ipreziv.
azilsartan medoxomil
azilsartanmedoksomil
“obstructive hypertrophic cardiomyopathy”).
Aortalna i mitralna stenoza, opstruktivna hipertrofična kardiomiopatija
Consequently, uptitration of Ipreziv and concomitant therapy may be needed more frequently for blood pressure control in black patients.
Posljedično tome, za kontrolu krvnog tlaka u bolesnika crne rase može biti potrebno postupno povećavati dozu Ipreziva i istovremeno davati dodatnu terapiju.
Ipreziv is for oral use.
Ipreziv se uzima kroz usta.
The incidence of adverse reactions with Ipreziv was not affected by gender, age, or race.
Spol, dob i rasa nisu utjecali na incidenciju nuspojava Ipreziva.
Ipreziv contains an active substance called azilsartan medoxomil and belongs to a class of medicines called angiotensin II receptor antagonists (AIIRAs).
Ipreziv sadrži djelatnu tvar po nazivu azilsartanmedoksomil i pripada skupini lijekova koji se zovu antagonisti receptora angiotenzina II . Angiotenzin II je tvar koja se prirodno nalazi u tijelu i uzrokuje stezanje krvnih žila te tako povisuje krvni tlak.
Adverse reaction
Način primjene
telmisartan, irbesartan).
Primjena kroz usta.
Uncommon side effects affecting less than 1 in 100 people: - Low blood pressure, which may make you feel faint or dizzy - Feeling tired - Swelling of the hands, ankles or feet (peripheral oedema) - Skin rash and itching - Nausea - Muscle spasms - Increased serum creatinine in the blood (an indicator of kidney function) - Increased uric acid in the blood (an indicator of kidney function).
Manje česte nuspojave koje se javljaju u manje od 1 na 100 osoba: - nizak krvni tlak, zbog čega možete osjećati sklonost nesvjestici ili omaglicu - osjećaj umora
Each tablet contains 20 mg azilsartan medoxomil (as potassium)
TVARI Jedna tableta sadrži 80 mg azilsartanmedoksomila (u obliku kalijeve soli)
24-Hour Mean SBP: LS Mean Change from Baseline (BL) to Week 6 (mm Hg) Study 1
6. tjedna (mm Hg) Ispitivanje Promjena od početne vrijednosti Ispitivanje Promjena od početne vrijednosti
Skin and subcutaneous tissue disorders
- oticanje šaka, gležnjeva ili stopala (periferni edemi) - osip i svrbež kože
o an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.
ili da Vam je debljina srčanog mišića neprirodno povećana (što se zove “opstruktivna hipertrofična kardiomiopatija”) - ako uzimate bilo koji od lijekova navedenih u nastavku, koji se koriste za liječenje visokog krvnog tlaka: o ACE inhibitor (primjerice enalapril, lisinopril, ramipril), osobito ako imate bubrežne tegobe povezane sa šećernom bolešću o aliskiren.
Marketing Authorisation Holder:
Veličine pakiranja:
Rash, pruritus Angioedema
- mučnina - grčevi mišića
Mannitol (E 421)
magnezijev stearat (E 572) 6.2 Inkompatibilnosti
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 40 mg azilsartan medoxomil (as potassium)
TVARI Jedna tableta sadrži 40 mg azilsartanmedoksomila (u obliku kalijeve soli).
Takeda Pharmaceuticals Croatia d.o.o.
Takeda Ireland Ltd.
The main measure of effectiveness was the increase in height of patients after one year of treatment.
Glavna mjera učinkovitosti bilo je povećanje visine bolesnika nakon jedne godine liječenja.
This summary was last updated in 07-2013.
Sažetak je posljednji put obnovljen 07-2013.
However, these antibodies do not seem to have an effect on the way the medicine works.
Međutim, čini se da ova protutijela nemaju učinak na djelovanje lijeka.
In addition, the company that markets Somatropin Biopartners will provide further long-term data on the effectiveness and safety of the medicine.
Nadalje, tvrtka koja stavlja u promet Somatropin Biopartners davat će dodatne dugoročne podatke o učinkovitosti i sigurnosti lijeka.
The full EPAR for Somatropin Biopartners can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za Somatropin Biopartners može se naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
It is used to treat children aged 2 to 18 years who are failing to grow normally because they do not have enough growth hormone.
Koristi se za liječenje djece od 2 do 18 godina s poremećajem u rastu jer nemaju dovoljno hormona rasta.
A risk management plan has been developed to ensure that Somatropin Biopartners is used as safely as possible.
Razvijen je plan upravljanja rizikom kako bi se osiguralo da se Somatropin Biopartners koristi što je sigurnije moguće.
In children, the recommended dose is 0.5 mg per kilogram body weight, injected once a week.
Kod djece preporučena doza je 0,5 mg po kilogramu tjelesne težine, ubrizgano jednom tjedno.
The dose may need to be adjusted, depending on the patient's response to treatment and the side effects the patient experiences.
Može biti potrebno prilagoditi dozu, ovisno o odgovoru bolesnika na liječenje i nuspojavama koje se jave kod bolesnika.
In adults, the recommended dose is 2 mg injected once a week, except for female patients also taking oral oestrogen who should receive 3 mg once a week.
Kod odraslih preporučena doza je 2 mg ubrizgano jednom tjedno, osim kod žena koje oralno uzimaju estrogene koje moraju primiti 3 mg jednom tjedno.
It promotes growth during childhood and adolescence, and also affects the way the body handles proteins, fat and carbohydrates.
Potiče rast tijekom djetinjstva i adolescencije te utječe na način na koji tijelo koristi bjelančevine, masti i ugljikohidrate.
The European Commission granted a marketing authorisation valid throughout the European Union for Somatropin Biopartners on 05.08.2013.
Europska komisija izdaje odobrenje za stavljanje u promet koje za Somatropin Biopartners vrijedi na prostoru Europske unije od 05.08.2013.
In adults, the most common side effects (which may affect more than 1 in 10 people) are swelling, mild hyperglycaemia (high blood sugar levels) and headache.
Najčešće nuspojave kod odraslih (koje se mogu javiti u više od 1 na 10 osoba) su oteklina, umjerena hiperglikemija (visoka razina šećera u krvi) i glavobolja.
The patient or caregiver can inject Somatropin Biopartners themselves, after training by a doctor or a nurse.
Bolesnik ili njegovatelj mogu sami ubrizgavati Somatropin Biopartners, nakon što ih uvježbaju liječnik ili sestra.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Somatropin Biopartners' benefits are greater than its risks and recommended that it be approved for use in the EU.
Povjerenstvo za lijekove za primjenu kod ljudi (CHMP) pri Agenciji odlučilo je da koristi od Somatropin Biopartners nadmašuju s njim povezane rizike te je preporučilo njegovo odobrenje za korištenje u Europskoj uniji.
Somatropin Biopartners is injected under the skin once a week.
Somatropin Biopartners se ubrizgava potkožno jednom tjedno.
It is also used in adults with a lack of growth hormone who may have either had growth hormone deficiency as children or developed it later during adulthood.
Koristi se i kod odraslih koji imaju manjak hormona rasta, a koji su imali manjak hormona rasta kao djeca ili su tijekom odrasle dobi razvili to stanje.
In adults who lack growth hormone, Somatropin Biopartners has a modest effect in decreasing body fat.
Kod odraslih koji imaju manjak hormona rasta Somatropin Biopartners ima skroman učinak u smanjenju tjelesne težine.
This is a summary of the European public assessment report (EPAR) for Somatropin Biopartners.
Ovo je sažetak Europskoga javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) za Somatropin Biopartners.
This study compared Somatropin Biopartners with placebo (a dummy treatment) and measured the decrease in body fat (which is normally high in adults with growth hormone deficiency) after 6 months of treatment.
Ovo ispitivanje je uspoređivalo Somatropin Biopartners s placebom (liječenje bez djelatne tvari) i mjerilo smanjenje tjelesne masti (koje je normalno visoko kod odraslih s manjkom hormona rasta) nakon 6 mjeseci liječenja.
Somatropin Biopartners must not be used in patients with an active tumour or an acute lifethreatening illness.
Somatropin Biopartners se ne smije koristiti kod bolesnika s aktivnim tumorom ili akutnom bolešću opasnom po život.
The study showed that Somatropin Biopartners was as effective as Genotropin at promoting growth: children receiving Somatropin Biopartners grew around 11.7 cm in one year, compared with 12.0 cm in children receiving Genotropin.
Ispitivanje je pokazalo da je lijek Somatropin Biopartners bio jednako učinkovit u poticanju rasta kao Genotropin: djeca koja su primala Somatropin Biopartners narasla su oko 11,7 cm u jednoj godini u usporedbi s 12,0 cm kod djece koja su primala Genotropin.
Somatropin Biopartners is a medicine that contains human growth hormone (also known as somatropin).
Somatropin Biopartners je lijek koji sadrži ljudski hormon rasta (poznat i kao somatropin).
It is not intended to provide practical advice on how to use Somatropin Biopartners.
Svrha sažetka nije davati praktične savjete o načinu korištenja lijeka Somatropin Biopartners.
Adults treated with Somatropin Biopartners had an average reduction of body fat of 1 kg while body fat in those treated with placebo increased by 0.5 kg.
Odrasli liječeni lijekom Somatropin Biopartners imali su prosječno smanjenje tjelesne masti od 1 kg, dok se tjelesna mast kod osoba liječenih placebom povećala za 0,5 kg.
In children, the most common side effects with Somatropin Biopartners (which may affect more than 1 in 10 people) are injection site swelling and development of antibodies (proteins that are produced in response to Somatropin Biopartners).
Kod djece, najčešće nuspojave Somatropin Biopartners (koje se mogu javiti u više od 1 na 10 osoba) su oteklina mjesta injekcije i razvijanje antitijela (bjelančevine koje se proizvode kao odgovor na Somatropin Biopartners).
What measures are being taken to ensure the safe and effective use of Somatropin Biopartners?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena Somatropin Biopartners?
Treatment with Somatropin Biopartners should be started and monitored by a doctor experienced in diagnosing and treating patients with growth hormone deficiency.
Liječenje sa Somatropin Biopartners mora započeti i nadzirati liječnik koji ima iskustva u dijagnosticiranju i liječenju bolesnika s manjkom hormona rasta.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Somatropin Biopartners, including the appropriate precautions to be followed by healthcare professionals and patients.
Na temelju tog plana u sažetak opisa svojstava lijeka kao i u uputu o lijeku za Somatropin Biopartners uključene su sigurnosne informacije uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
It is produced by a method known as ‘recombinant DNA technology': the hormone is made by yeast cells into which a gene (DNA) has been introduced that makes them able to produce it. Somatropin Biopartners replaces the natural hormone.
Proizvodi se metodom pod nazivom „tehnologija rekombinantne DNA": hormon proizvode stanice kvasca u koje je unesen gen (DNA) koji im omogućuje proizvodnju.
The study compared Somatropin Biopartners given once a week with another somatropin-containing medicine called Genotropin given once a day.
Ispitivanje je uspoređivalo lijek Somatropin Biopartners primjenjivan jednom tjedno s drugim lijekom koji sadrži somatropin pod nazivom Genotropin primjenjivan jednom dnevno.
Other information about Somatropin Biopartners
Druge informacije o Somatropin Biopartners
For more information about treatment with Somatropin Biopartners, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Više informacija o liječenju Somatotropin Biopartners, pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
The active substance in Somatropin Biopartners, somatropin, is identical to the human growth hormone.
Djelatna tvar lijeka Somatropin Biopartners, somatropin, identična je ljudskom hormonu rasta.
Somatropin Biopartners has been studied in one main study involving 180 children with a lack of growth hormone.
Somatropin Biopartners je ispitivan u jednom glavnom ispitivanju koje je uključivalo 180 djece s manjkom hormona rasta.
For practical information about using Somatropin Biopartners, patients should read the package leaflet or contact their doctor or pharmacist.
Praktične informacije o korištenju Somatropin Biopartners bolesnici trebaju pročitati u uputi o lijeku ili se obratiti svom liječniku ili ljekarniku.
Somatropin Biopartners is available as a powder and solvent which are made into a suspension for injection.
Somatropin Biopartners je dostupan u obliku praška i otapala za suspenziju za injekciju.
What is Somatropin Biopartners and what is it used for?
Što je Somatropin Biopartners i za što se koristi?
Regarding its safety, the side effects reported with Somatropin Biopartners were similar to those of other daily somatropin medicines, with the exception of increased injection site reactions in children, which should be balanced against the convenience of weekly injections.
U odnosu na sigurnost, nuspojave prijavljene s lijekom Somatropin Biopartners bile su slične onima s drugim lijekovima koji sadrže somatropin i primjenjuju se dnevno, s iznimkom reakcija na mjestu injekcije kod djece, koje donose prevagu u korist tjednih injekcija.
Somatropin Biopartners has also been studied in one main study involving 151 adults with growth hormone deficiency.
Somatropin Biopartners se ispitivao i u jednom glavnom ispitivanju koje je uključivalo 151 odraslu osobu s manjkom hormona rasta.
What are the risks associated with Somatropin Biopartners?
Koji su rizici povezani s Somatropin Biopartners?
The Committee concluded that Somatropin Biopartners is as effective in children who fail to grow normally as other somatropin-containing treatments given daily.
Povjerenstvo je zaključilo da je Somatropin Biopartners učinkovit kod djece s poremećajem rasta kao i druga liječenja koja sadrže somatropin i primijenjuju se dnevno.
Why is Somatropin Biopartners approved?
Zašto je Somatropin Biopartners odobren?
For the full list of all side effects reported with Somatropin Biopartners, see the package leaflet.
Potpuni popis nuspojava koje su zabilježene sa Somatropin Biopartners potražite u uputi o lijeku.
Growth hormone is a substance secreted by the pituitary gland (a gland located at the base of the brain).
Hormon rasta je tvar koju izlučuje hipofiza (žlijezda smještena na bazi mozga).
What benefits of Somatropin Biopartners have been shown in studies?
Koje koristi Somatropin Biopartners su dokazane u ispitivanjima?
How is Somatropin Biopartners used?
Kako se Somatropin Biopartners koristi?
How does Somatropin Biopartners work?
Kako Somatropin Biopartners djeluje?
Safety and efficacy have not been established in the following:
Sigurnost i djelotvornost nisu ustanovljene kod sljedećeg:
EU/1/07/390/001 EU/1/07/390/002 EU/1/07/390/003 EU/1/07/390/004
EU/1/07/390/002 EU/1/07/390/003 EU/1/07/390/004
Discard open tubes 7 days after opening, even if they are not empty.
Otvorene tube bacite 7 dana nakon otvaranja, čak i ako nisu prazne.
CI: confidence interval.
CI: interval pouzdanosti.
Wash your hands before and after applying the ointment.
Operite ruke prije i nakon nanošenja masti.
Neither of these findings is of clinical relevance.
Niti jedan od tih nalaza nije klinički značajan.
Apply the ointment as soon as you remember, and apply the next dose at the usual time.
Namažite mast čim se sjetite, a sljedeću dozu primijenite u uobičajeno vrijeme.
Care must be taken to avoid ingestion.
Potreban je oprez kako bi se izbjegla ingestija.
Elderly (aged 65 and older)
Stariji (65 godina i stariji)
Other medicines and Altargo
Drugi lijekovi i Altargo
It must not be put in the eyes, on the mouth or lips, inside the nose or inside the female genital area.
Ne smije se stavljati u oči, u usta ili na usne, u nos ili na područje ženskog spolovila.
If you stop using Altargo too soon, the bacteria may start to grow again and your infection may come back.
Ako prestanete primjenivati Altargo prerano, bakterije mogu opet početi rasti i infekcija Vam se može vratiti.
Confidence interval was not adjusted for multiplicity.
Interval pouzdanosti nije bio prilagođen za mnogostrukost.
Currently available data are described in section 5.2, but no recommendation on a
Trenutno dostupni podaci opisani su u dijelu 5.2, međutim nije moguće dati preporuku o doziranju.
If the patient is a child less than two years old it is especially important that you tell your doctor about any other medicines that the child is being given, including medicines bought without a prescription.
Ako je bolesnik dijete koje je mlađe od dvije godine, posebno je važno da svog liječnika upozorite na sve lijekove koje dijete prima, uključujući i lijekove koji se mogu nabaviti bez recepta.
95% Exact CI
95% točan CI
In patients aged less than 18 years the total surface area treated should be no more than 2% of the body surface area.
U bolesnika mlađih od 18 godina liječena površina ne smije biti veća od 2% ukupne površine tijela.
Retapamulin is approximately 94% bound to human plasma proteins.
Približno 94% retapamulina veže se za ljudske proteine plazme.
Altargo is not expected to affect your ability to drive or use machines.
Ne očekuje se da će Altargo utjecati na Vašu sposobnost upravljanja vozilima i strojevima.
Tell your doctor if you are using, have recently used or might use any other medicines.
Obavijestite svog liječnika ako uzimate ili ste nedavno uzeli ili biste mogli uzeti bilo koje druge lijekove.